UBS Group’s Strata Critical Medical Inc Warrants SRTAW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,279
Closed -$138 10512
2025
Q4
$138 Buy
+1,279
New +$212 ﹤0.01% 10152
2024
Q2
Sell
-54
Closed -$6 9538
2024
Q1
$6 Buy
+54
New +$9 ﹤0.01% 9131
2023
Q4
Sell
-69
Closed -$16 9324
2023
Q3
$16 Buy
+69
New +$32 ﹤0.01% 9156
2023
Q1
Sell
-927
Closed -$464 9623
2022
Q4
$464 Sell
927
-6,072
-87% -$3.88K ﹤0.01% 10174
2022
Q3
$4K Buy
6,999
+641
+10% +$543 ﹤0.01% 9333
2022
Q2
$4K Buy
6,358
+5,463
+610% +$8.29K ﹤0.01% 9041
2022
Q1
$2K Sell
895
-5,000
-85% -$7.86K ﹤0.01% 9610
2021
Q4
$13K Buy
5,895
+4,737
+409% +$11.6K ﹤0.01% 8434
2021
Q3
$3K Sell
1,158
-1,307
-53% -$2.73K ﹤0.01% 8792
2021
Q2
$7K Buy
+2,465
New +$5.37K ﹤0.01% 8311

Other funds holding SRTAW

UBS Group's SRTAW Position: Q1 2026 in Review

UBS Group sold out of Strata Critical Medical Inc Warrants (SRTAW) in Q1 2026, closing a stake of 1,279 shares — an estimated $138 sold.

UBS Group first reported a position in SRTAW in Q2 2021 and held it in 10 quarters. The position peaked at $13K in Q4 2021. 8 funds tracked by Wall St. Rank hold SRTAW as of Q1 2026.

  • UBS Group reported no remaining Strata Critical Medical Inc Warrants position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 1,279 Strata Critical Medical Inc Warrants shares in Q1 2026, an estimated $138.
  • UBS Group first reported a position in Strata Critical Medical Inc Warrants in Q2 2021 and held it in 10 quarters.
  • UBS Group's Strata Critical Medical Inc Warrants position peaked at $13K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Strata Critical Medical Inc Warrants as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.